COVID-19 Clinical Trial
Official title:
A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants 18-84 Years of Age in the United Kingdom
| Verified date | April 2023 |
| Source | Novavax |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This is a study to evaluate the efficacy, immune response, and safety of a coronavirus disease 2019 (COVID-19) vaccine called SARS-CoV-2 rS with Matrix-M1 adjuvant in adults aged 18-84 years in the United Kingdom. A vaccine causes the body to have an immune response that may help prevent the infection or reduce the severity of symptoms. An adjuvant is something that can make a vaccine work better. This study will look at the protective effect, body's immune response, and safety of SARS-CoV-2 rS with Matrix-M1 adjuvant in the study population. Participants in the study will randomly be assigned to receive SARS-CoV-2 rS with Matrix-M1 adjuvant or placebo. Each participant in the study will receive a total of 2 intramuscular injections over the course of the study. Approximately 15,000 participants will take part in the study. The first approximately 400 participants who meet additional criteria will receive a flu vaccine, in addition to the SARS-CoV-2 rS vaccine or placebo, as part of a sub-study. An effort will be made to enroll a target of at least 25% of participants who are ≥ 65 years of age, as well as prioritizing other groups that are most affected by COVID-19, including racial and ethnic minorities. Unblinding of treatment assignment may occur in order to allow a participant to make an informed decision regarding receipt of an already approved or deployed SARS-CoV-2 vaccine. Participants who choose to receive an approved or deployed SARS-CoV-2 vaccine as per UK government guidance will be encouraged to remain in the study for scheduled safety assessments.
| Status | Completed |
| Enrollment | 15138 |
| Est. completion date | March 29, 2022 |
| Est. primary completion date | March 29, 2022 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 84 Years |
| Eligibility | Inclusion Criteria: - Able and willing to comply with all study requirements. - Willing to allow investigators to discuss medical history with their General Practitioner and access all relevant medical records. - Willing and able to give informed consent. - Women of child-bearing potential must agree not to have sexual intercourse with men, or must consistently use an agreed method of contraception, from at least 28 days prior to enrolment in the study, through 3 months after the last vaccination. - Room air oxygen saturation > 95% at Screening/Day 0. - Seasonal Flu Vaccine Co-Administration Sub-Study only: Participant should not have received a current season flu vaccine, should have no reason why the specific sub-study flu vaccine cannot be administered, and should not have any prior history of allergy or severe reaction to seasonal flu vaccines. Exclusion Criteria: - Participation in other COVID-19 vaccine or preventative drug trials for the duration of the study. - Future participation in any blood tests for the duration of the study where participants are informed of their levels of COVID-19 antibodies or antigens. - Participation in any trial involving an investigational drug, biologic or device within 45 days prior to the first study vaccination. - History of laboratory-confirmed COVID-19 infection any time prior to first study vaccination. - Receipt of any immunoglobulins and/or any blood products within 3 months prior to planned administration of study vaccine. - Any confirmed or suspected immunosuppressive or immunodeficient state. Chronic administration (defined as more than 14 continuous days) of immunosuppressant medication within the past 3 months, except topical steroids or short-term oral steroids (course lasting = 14 days). Note: An immunosuppressant dose of glucocorticoid is defined as a systemic dose = 10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted if other chronic disease conditions do not exclude a participant from the study. - History of allergic disease or reactions likely to be made worse by any component of the study vaccines. - History of anaphylaxis to any prior vaccine. - Pregnancy, breast-feeding or willingness/intention to become pregnant within 3 months following the last study vaccination. - Current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ. - Bleeding disorder, or prior history of significant bleeding or bruising following intramuscular injections or venepuncture (e.g. to draw blood for tests). - Continuous use of anticoagulants or anti-platelet agents. Note: The preventative use of = 325 mg of aspirin per day is permitted. - Suspected or known current alcohol or drug dependency. - Study team member or first-degree relative of any study team member (inclusive of sponsor, contract research organization (CRO), and site personnel involved in the study). - Participants having any current workup of undiagnosed illness within 8 weeks prior to start of study which could lead to new condition or diagnosis. - Received any live vaccine within 4 weeks or any vaccine (excluding flu) within 2 weeks prior to first study vaccination; or any licensed flu vaccine within 1 week prior to first study vaccination or plans to receive any vaccine from these time periods until 28 days after the second study vaccination. - Have clinically significant chronic cardiovascular, endocrine (hormones), gastrointestinal, hepatic (including hepatitis B and C), renal (kidney), neurological, respiratory, psychiatric or other medical disorders not excluded by other exclusion criteria, that are assessed by the investigator as being clinically unstable within the prior 4 weeks as evidenced by: a) Hospitalisation for the condition, including day surgical interventions; b) New significant organ function deterioration; or c) Needing addition of new treatments or major dose adjustments of current treatments (mild or moderate well-controlled comorbidities are allowed). - History of chronic neurological disorders that have required prior specialist physician review for diagnosis and management (such as multiple sclerosis, dementia, transient ischemic attacks, Parkinson's disease, degenerative neurological conditions, and neuropathy) or a history of stroke or previous neurological disorder within 12 months with residual symptoms. Participants with a history of migraine or chronic headaches or nerve root compression that have been stable on treatment for the last 4 weeks are not excluded. - Any autoimmune disease/condition (iatrogenic or congenital). - Any other significant disease, disorder or finding that, in the opinion of the investigator, may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study, or impair interpretation of the study data. - Participant requires the use of continuous oxygen therapy or any oxygen therapy while awake or is anticipated to require daytime oxygen therapy during the course of the study. Other protocol-defined inclusion/exclusion criteria may apply. |
| Country | Name | City | State |
|---|---|---|---|
| United Kingdom | Aberdeen Royal Infirmary (Site UK007), Foresterhill | Aberdeen | |
| United Kingdom | Belfast Health and Social Care Trust (BHSCT) (Site UK011) | Belfast | Antrim |
| United Kingdom | Blackpool Teaching Hospitals (Site UK010) | Blackpool | Lancashire |
| United Kingdom | Bradford Teaching Hospitals NHS Trust (Site UK018) | Bradford | |
| United Kingdom | Synexus Wales Clinical Research Centre (Site UK025) | Cardiff | |
| United Kingdom | Synexus Lancashire Clinical Research Centre (Site UK022) | Chorley | |
| United Kingdom | Colchester Hospital (Site UK034) | Colchester | |
| United Kingdom | Lakeside Healthcare, Lakeside Surgery (Site UK005) | Corby | Northants |
| United Kingdom | Synexus Midlands Clinical Research Centre (Site UK024) | Edgbaston | Birmingham |
| United Kingdom | Royal Devon and Exeter Hospital (Site UK013) | Exeter | Devon |
| United Kingdom | AES - Glasgow (Site UK033) | Glasgow | |
| United Kingdom | Queen Elizabeth University Hospital (Site UK008) | Glasgow | Lanarkshire |
| United Kingdom | Royal Free (Site UK012) | Hampstead | London |
| United Kingdom | University Hartlepool Hospital (Site UK021) | Hartlepool | |
| United Kingdom | Synexus Hexham Clinical Research Centre (Site UK023) | Hexham | |
| United Kingdom | Royal Lancaster Infirmary (Site UK029) | Lancaster | |
| United Kingdom | Research & Innovation Centre, St. James's University Hospital (Site UK019) | Leeds | |
| United Kingdom | Chelsea & Westminster NHS Foundation Trust (Site UK006) | London | |
| United Kingdom | St. Thomas' Hospital (Site UK020) | London | |
| United Kingdom | "Maidstone Hospital - Central Research and Development Office Above Breast Care Centre - 1st Floor" (Site UK028) | Maidstone | Kent |
| United Kingdom | AES - Synexus Manchester (Site UK032) | Manchester | |
| United Kingdom | Norfolk and Norwich University Hospital NHS Foundation Trust, Norfolk and Norwich University Hospital (Site UK015) | Norwich | |
| United Kingdom | Salford Hospital (Site UK030) | Oldham | Lancashire |
| United Kingdom | Warneford Hospital (Site UK016) | Oxford | Oxfordshire |
| United Kingdom | Wansford and Kingscliffe Practice (Site UK035) | Peterborough | |
| United Kingdom | AES - Synexus Thames Valley (Site UK031) | Reading | |
| United Kingdom | University Hospital Southampton NHS Foundation Trust (UHS) (Site UK014) | Southampton | |
| United Kingdom | Midlands Partnership NHS Foundation Trust Headquarters (Site UK017) | Stafford | |
| United Kingdom | Stockport NHS Foundation Trust (Site UK009) | Stockport | |
| United Kingdom | St. George's University Hospitals NHS Foundation Trust Clinical Research Facility (Site UK001) | Tooting | London |
| United Kingdom | The Royal Cornwall Hospitals NHS Trust (Site UK036) | Truro | Cornwall |
| United Kingdom | Synexus Merseyside Clinical Research Centre (Site UK026) | Waterloo | Liverpool |
| United Kingdom | North Wales Clinical Research Centre (NWCRC) (Site UK027) | Wrexham | North Wales |
| Lead Sponsor | Collaborator |
|---|---|
| Novavax |
United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Participants with Symptomatic Mild, Moderate, or Severe Coronavirus Disease 2019 (COVID-19) | Number of participants, testing serologically negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at baseline, with first occurrence of positive (+) polymerase chain reaction (PCR)-confirmed SARS-CoV-2 illness with symptomatic mild, moderate, or severe COVID-19 with onset from Day 28 through the length of the study. | From Day 28 to Day 386 | |
| Secondary | Participants with Symptomatic Moderate or Severe COVID-19 | Number of participants, testing serologically negative for SARS-CoV-2 at baseline with first occurrence of (+) PCR-confirmed, SARS-CoV-2 illness with symptomatic moderate or severe COVID-19 with onset from Day 28 through the length of the study. | From Day 28 to Day 386 | |
| Secondary | Participants with Symptomatic Severe COVID-19 | Number of participants, testing serologically negative for SARS-CoV-2 at baseline with first occurrence of (+) PCR-confirmed, SARS-CoV-2 illness with symptomatic severe COVID-19 with onset from Day 28 through the length of the study. | From Day 28 to Day 386 | |
| Secondary | Participants with Symptomatic Mild, Moderate, or Severe COVID-19 Regardless of Baseline Serostatus | Number of participants, regardless of serostatus at baseline, with first occurrence of (+) PCR-confirmed, SARS-CoV-2 illness with symptomatic mild, moderate, or severe COVID-19 assessed from Day 28 through the length of the study. | From Day 28 to Day 386 | |
| Secondary | Participants with Asymptomatic or Symptomatic COVID-19 | Number of participants, regardless of serostatus at baseline, with first occurrence of (+) PCR-confirmed, or nucleocapsid protein serologically confirmed, SARS-CoV-2 illness with asymptomatic or symptomatic COVID-19 with onset from Day 28 through the length of the study. | From Day 28 to Day 386 | |
| Secondary | Participants with COVID-19 requiring Hospitalization, Intensive Care Unit (ICU), or Mechanical Ventilation | Number of participants, regardless of serostatus at baseline, with first occurrence of (+) PCR-confirmed, SARS-CoV-2 illness with COVID-19 with onset from Day 28 through the length of the study. | From Day 28 to Day 386 | |
| Secondary | Participants with Symptomatic Mild COVID-19 | Number of participants, regardless of serostatus at baseline, with first occurrence of (+) PCR-confirmed, SARS-CoV-2 illness with symptomatic mild COVID-19 (with no progression to moderate or severe COVID-19 during the course of the COVID-19 episode) with onset from Day 28 through the length of the study. | From Day 28 to Day 386 | |
| Secondary | Serum IgG Antibody Levels at Multiple Time Points Expressed as Geometric Mean ELISA Units (GMEUs) | Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by enzyme-linked immunosorbent assay (ELISA) expressed as GMEUs at Day 0 and Day 35. | Day 0 to Day 35 | |
| Secondary | Participants with Serious Adverse Events (SAEs) | Number of participants with SAEs through the length of the study by Medical Dictionary for Regulatory Activities (MedDRA) classification and relationship to study vaccination. | 386 days | |
| Secondary | Participants with Medically Attended Adverse Events (MAAEs) Related to Study Vaccination | Number of participants with MAAEs related to study vaccination through the length of the study by MedDRA classification. | 386 days | |
| Secondary | Participants with Adverse Events of Special Interest (AESIs) | Number of participants with AESIs, which include potential immune-mediated medical conditions (PIMMCs) and AESIs relevant to COVID-19 such as possible vaccine-enhanced disease by MedDRA classification through the length of the study. | 386 days | |
| Secondary | Participants with Solicited Local and Systemic Adverse Events (AEs) | Number of participants with solicited local and systemic AEs for 7 days after each study vaccination. | 28 days | |
| Secondary | Participants with All MAAEs Through Day 35 | Number of participants with all MAAEs through Day 35 by MedDRA classification and relationship to study vaccination. | 35 days | |
| Secondary | Participants with Unsolicited AEs Through Day 49 | Number of participants with unsolicited AEs through Day 49 by MedDRA classification and relationship to study vaccination. | 49 days |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
| Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
| Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
| Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
| Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
| Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
| Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
| Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
| Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
| Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
| Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
| Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
| Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
| Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
| Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
| Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
| Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|